Revision 1
#8155
Store at -20C
877-616-CELL (2355)
877-678-TECH (8324)
3 Trask Lane | Danvers | Massachusetts | 01923 | USA
For Research Use Only. Not for Use in Diagnostic Procedures.
Applications:
W, IP
Reactivity:
H M R Mk
Sensitivity:
Endogenous
MW (kDa):
80-84
Source/Isotype:
Rabbit IgG
UniProt ID:
#Q9NYJ8
Entrez-Gene Id:
23118
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:100 |
Storage
Specificity/Sensitivity
Phospho-TAB2 (Ser372) (D5A4) Rabbit mAb recognizes endogenous levels of TAB2 protein only when phosphorylated at Ser372.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser372 of human TAB2 protein.
Background
TAK1 is a mitogen-activated protein kinase kinase kinase activated by TGF-β and various pro-inflammatory signals (1,2). In vivo, TAK1 activation requires its association with TAK1 binding protein 1 (TAB1), which triggers TAK1 autophosphorylation at Thr184 and Thr187 (3,4). The TAB2 adaptor protein links TAK1 with TRAF6 to mediate TAK1 activation following IL-1 stimulation (5). Once activated, TAK1 phosphorylates the MAPK kinases MKK4 and MKK3/6, which activate JNK and p38 MAPK, respectively. TAK1 and TRAF6 also activate the NF-κB pathway by phosphorylating the NF-κB inducing kinase (NIK) to trigger subsequent activation of IKK (2,6). In addition to TAK1, TAB1 interacts with and activates p38α MAPK (7). Targeted disruption of the TAB1 gene in mice causes a drastic reduction in TAK1 activity and leads to embryonic lethality (8).
TAK1 is associated with TAB1 as well as either TAB2 or TAB3 (9). Activation of TAK1 is triggered by K63-ubiquitination of TRAF6, resulting in binding to TAB2 and TAB3 and autophosphorylation of TAK1 (10-12). Multiple phosphorylation sites have been identified in all three TAB family members that are triggered by IL-1 (13,14). TAB2 phosphorylation was identified at Ser372 and Ser524 (14).
Background References
- Yamaguchi, K. et al. (1995) Science 270, 2008-11.
- Ninomiya-Tsuji, J. et al. (1999) Nature 398, 252-6.
- Shibuya, H. et al. (1996) Science 272, 1179-82.
- Sakurai, H. et al. (2000) FEBS Lett 474, 141-5.
- Takaesu, G. et al. (2000) Mol Cell 5, 649-58.
- Wang, C. et al. (2001) Nature 412, 346-51.
- Ge, B. et al. (2002) Science 295, 1291-4.
- Komatsu, Y. et al. (2002) Mech Dev 119, 239-49.
- Cheung, P.C. et al. (2004) Biochem J 378, 27-34.
- Kishida, S. et al. (2005) Genes Cells 10, 447-54.
- Sato, Y. et al. (2009) EMBO J 28, 3903-9.
- Kanayama, A. et al. (2004) Mol Cell 15, 535-48.
- Cheung, P.C. et al. (2003) EMBO J 22, 5793-805.
- Mendoza, H. et al. (2008) Biochem J 409, 711-22.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
W: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: Human M: Mouse R: Rat Hm: Hamster Mk: Monkey Vir: Virus Mi: Mink C: Chicken Dm: D. melanogaster X: Xenopus Z: Zebrafish B: Bovine Dg: Dog Pg: Pig Sc: S. cerevisiae Ce: C. elegans Hr: Horse GP: Guinea Pig Rab: Rabbit G: Goat All: All Species Expected
Trademarks and Patents
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.